Acoramidis, an oral therapy, is now approved to reduce cardiovascular-related deaths and hospitalizations in adults with hereditary or wild-type ATTR-CM.
It is the first sodium-glucose co-transporter 2 inhibitor to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.
The FDA has proposed new draft guidance to improve the accuracy of pulse oximeters across all skin tones, addressing long-standing concerns about potential disparities in performance.
